Latest News and Press Releases

Marks the first-ever in vivo delivery of an experimental CRISPR gene editing medicine to a pediatric patient Company on track to complete dosing of the pediatric mid-dose cohort in the first...

Preclinical data demonstrate that edited iNK cells result in increased persistence, enhanced anti-tumor activity and extended survival supporting continued development as a novel therapeutic approach...

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the U.S. Patent and Trademark Office (USPTO) issued...

EDIT-101 Phase 1/2 BRILLIANCE trial enrolling mid-dose pediatric cohort; clinical data update expected in 2H 2022 EDIT-301 remains on track to dose first sickle cell disease patient in 1H 2022 and...

CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast...

Anticipated 2022 milestones include initial clinical data for EDIT-301 in sickle cell disease by year-end, dosing of first TDT patient with EDIT-301, initiation of pediatric high-dose cohort for...

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview and update at the...

EDIT-301 is in development as a transformative, one-time treatment for people living with transfusion-dependent beta thalassemia Editas Medicine will initiate a Phase 1/2 clinical trial in 2022 ...

Preclinical data demonstrating Editas-engineered AsCas12a multiplexed editing of iPSCs enhances iNK tumor killing ability, supporting promise as a potential therapeutic approach for solid tumors iNKs...

CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced preclinical data on its progress in the development of...